HC Wainwright Cuts Price For This Small Cap 'Reflecting Potential Pause In Hemophilia Program'

Earlier this month, Freeline Therapeutics Holdings PLC FRLN reported 2Q22 earnings focusing on the pipeline's progress.
Notably, the company said it is evaluating strategic options for FLT180a for hemophilia B and is reviewing how to streamline operations, including but not limited to seeking a partner to enable the continuation of FLT180a through Phase 3 development.
Till the details on this potential pact are available, HC Wainwright is removing FLT180a from the model resulting in a price target of $15 from $20.
The company expects an update from the Phase 1/2 trial (MARVEL-1) evaluating FLT190 in Fabry disease in 2H22.
Dosing in the Phase 1/2 trial (GALILEO-1) evaluating FLT201 in Gaucher disease is expected to commence in 2H22, with initial data expected in 1H23.
HC Wainwright writes, "we look forward to continued progress on the lead programs to drive robust shareholder value over the next year."
Price Action: FRLN shares are down 3.16% at $0.92 on the last check Monday.